Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 2

Current and emerging therapies for the treatment of age-related macular degeneration

Authors M Vaughn Emerson, Andreas K Lauer

Published Date June 2008 Volume 2008:2(2) Pages 377—388

DOI http://dx.doi.org/10.2147/OPTH.S1485

Published 30 June 2008

M Vaughn Emerson, Andreas K Lauer

Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA

Abstract: Age-related macular degeneration (AMD) is the leading cause of vision loss in the industrialized world. In the last few decades, the mainstay of treatment for choroidal neovascularization (CNV) due to AMD has been thermal laser photocoagulation. In the last decade, photodynamic therapy with verteporfin extended treatment for more patients. While both of these treatments have prevented further vision loss in a subset of patients, improvement in visual acuity is rare. Anti-vascular endothelial growth factor A (VEGF) therapy has revolutionized the treatment of AMD-related CNV. Pegaptanib, an anti-VEGF aptamer prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment and bevacizumab, a full-length humanized monoclonal antibody against VEGF have both shown promising results with improvements in visual acuity with either agent. VEGF trap, a modified soluble VEGF receptor analogue, binds VEGF more tightly than all other anti-VEGF agents and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering ribonucleic acid (RNA) to inhibit VEGF production and VEGF receptor production. Steroids, including anecortave acetate in the treatment and prevention of CNV, have shown promise in controlled trials. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Other growth factors, including pigment epithelium-derived growth factor that has been administered via an adenoviral vector has shown promising initial results. In some patients ciliary neurotrophic factor is currently being studied for the inhibition of progression of geographic atrophy. Combination therapy has been investigated, and may prove to be more effective in the management of AMD-associated CNV. Ongoing and future studies will be crucial for optimizing the treatment of patients with AMD.

Keywords: age related macular degeneration, macular degeneration, VEGF, VEGF antagonist, anti-VEGF, choroidal neovascularization

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Basic training module for vitreoretinal surgery and the Casey Eye Institute Vitrectomy Indices Tool for Skills Assessment

Yeh S, Chan-Kai BT, Lauer AK

Clinical Ophthalmology 2011, 5:1249-1256

Published Date: 1 September 2011

Electroretinographic findings in transplant chorioretinopathy

Brian T Chan-Kai, Steven Yeh, Richard G Weleber, et al

Clinical Ophthalmology 2010, 4:777-783

Published Date: 14 July 2010

Readers of this article also read:

Fabrication of genistein-loaded biodegradable TPGS-b-PCL nanoparticles for improved therapeutic effects in cervical cancer cells

Zhang H, Liu G, Zeng X, Wu Y, Yang C, Mei L, Wang Z, Huang L

International Journal of Nanomedicine 2015, 10:2461-2473

Published Date: 27 March 2015

Cross-cultural adaptation and reliability testing of the Tilburg Frailty Indicator for optimizing care of Polish patients with frailty syndrome

Uchmanowicz I, Jankowska-Polańska B, Łoboz-Rudnicka M, Manulik S, Łoboz-Grudzień K, Gobbens RJJ

Clinical Interventions in Aging 2014, 9:997-1001

Published Date: 25 June 2014

Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging

Jie L-Y, Cai L-L, Wang L-J, Ying X-Y, Yu R-S, Zhang M-M,Du Y-Z

International Journal of Nanomedicine 2012, 7:3981-3989

Published Date: 24 July 2012

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes

Magnus Dencker, Martin Stagmo, Mozhgan Dorkhan

Vascular Health and Risk Management 2010, 6:373-382

Published Date: 18 May 2010

Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease

Felix C Ringshausen, Ai-Yui M Tan, Tobias Allander, Irmgard Borg, Umut Arinir, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:111-117

Published Date: 4 February 2009

Misregulation of rhodopsin phosphorylation and dephosphorylation found in P23H rat retinal degeneration

Yoshiyuki Saito, Hiroshi Ohguro, Ikuyo Ohguro, Noriyuki Sato, Futoshi Ishikawa, et al

Clinical Ophthalmology 2008, 2:821-828

Published Date: 30 October 2008